Hasnyálmirigyrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• KRAS 66
• PD-1 39
• TP53 4
• mTOR 0
• PI3K 0
• STAT3 0
• PD-L1 20
• CLDN18 21
• EGFR 11
• RAS 17
• BRCA2 8
• AKT 0
• BRCA1 10
• ERK 0
• MAPK 1
• PARP 9
• STING 0
• HER2 13
• MYC 0
• YAP 0
• MEK 5
• PALB2 9
• CTLA-4 9
• VEGF 3
• AMPK 0
• ATM 3
• CD40 2
• CXCR4 0
• HIF-1 0
• JNK 0
• NRF2 0
• CDKN2A 3
• GLP-1 2
• NRAS 5
• PRMT5 6
• IL-6 0
• PPAR 0
• PTEN 0
• BCL-2 0
• FAK 1
• IL-15 1
• JAK 0
• TROP2 3
• BRAF 2
• MET 2
• B7-H3 2
• CDK4/6 0
• CTNNB1 0
• FGFR 1
• HSP90 0
• HDAC 0
• KEAP1 1
• CD47 0
• METTL3 0
• MUC1 3
• AXL 1
• CCR5 0
• HER3 1
• HMGB1 1
• NTRK 1

2220 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Assessing autophagic dependencies in the context of RAS inhibition in pancreatic ductal adenocarcinoma

  Univ of North Carolina Chapel Hill· Chapel Hill, Egyesült Államok· 37 011 USD awarded in fiscal year 2026· until 2029. szept.

• FDA · R01

  Safety and Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in Pancreatic Cancer Patients

  Marker Therapeutics, Inc.· Houston, Egyesült Államok· 645 493 USD awarded in fiscal year 2026· until 2030. aug.

• NIH NIAMS · R21

  Nuclear Receptors In Cancer Cachexia

  University of Texas Hlth Sci Ctr Houston· Houston, Egyesült Államok· 200 604 USD awarded in fiscal year 2026· until 2028. júl.

• NIH NCI · U01

  The role of circadian gene regulation in pancreatic cancer progression and immune evasion

  University of Rochester· Rochester, Egyesült Államok· 626 555 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NIAMS · R56

  Mitochondrial permeability transition in cancer cachexia

  University of Florida· Gainesville, Egyesült Államok· 307 000 USD awarded in fiscal year 2026· until 2027. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  Immunity under Pressure: Mapping Compression Driven Tumor–Immune Rewiring to Potentiate Immunotherapy in Pancreatic Cancer (MechanoImmunoMap)

  University of Cyprus· Nicosia, Ciprus· EU contribution 1 500 000 EUR· until 2032. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glycoengineering for Immune Modulation in Precision Anti-Cancer Therapies (GlycoIMPACT)

  Universitat Wien· Wien, Ausztria· EU contribution 230 185 EUR· until 2028. dec.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-Generation Radiopharmaceuticals for Glioblastoma and Pancreatic Cancer: A 3D Perspective (radio3D)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spanyolország· EU contribution 4 366 500 EUR· until 2030. dec.· 9 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Evoking anti-tumor immunity in pancreatic cancer (Evoke-PDAC)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 2 497 125 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Görögország· EU contribution 796 590 EUR· until 2030. dec.· 7 countries

10 of 864 running projects, newest first. Listed amounts together: 465,0 M USD + 177,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers

  NCT07097064· Institut du Cancer de Montpellier - Val d'Aurelle· Frissítve: 2026. nov. 12.

  “The study was withdrawn prior to enrollment due to lack of funding”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Fecal Microbial Transplants for the Treatment of Pancreatic Cancer

  NCT04975217· M.D. Anderson Cancer Center· Frissítve: 2026. nov. 10.

  “PI request”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT05723107· NYU Langone Health· Frissítve: 2026. nov. 6.

  “Halted prematurely”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  CT-95 in Advanced Cancers Associated With Mesothelin Expression

  NCT06756035· Context Therapeutics Inc.· Frissítve: 2026. nov. 5.

  “The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer

  NCT07377526· M.D. Anderson Cancer Center· Frissítve: 2026. nov. 3.

  “PI Request”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

  NCT05685602· National Cancer Institute (NCI)· Frissítve: 2026. nov. 3.

  “Drug Supply Issues”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

  NCT05911243· University of Washington· Frissítve: 2026. nov. 3.

  “Study closed per SRC Low Accrual Policy.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

  NCT05057715· University of Pennsylvania· Frissítve: 2026. okt. 29.

  “Sponsor decision”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

  NCT04111172· Thomas Jefferson University· Frissítve: 2026. okt. 28.

  “Protocol is with FDA review, waiting for funding to be released”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  ZN-c3 + Gemcitabine in Pancreatic Cancer

  NCT06015659· Brandon Huffman, MD· Frissítve: 2026. okt. 27.

  “Study stopped early due to reaching the minimum number of DLTs required for halting the study due to toxicity.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

  NCT01950572· National Cancer Institute (NCI)· Forrás

• Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

  NCT04750954· National Cancer Institute (NCI)· Forrás

• Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

  NCT04172532· National Cancer Institute (NCI)· Forrás

• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  NCT01174121· National Cancer Institute (NCI)· Forrás

• Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

  NCT04907643· Cedars-Sinai Medical Center· Forrás

• Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

  NCT05053971· National Cancer Institute (NCI)· Forrás

• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

  NCT04550494· National Cancer Institute (NCI)· Forrás

• Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

  NCT03816358· National Cancer Institute (NCI)· Forrás

• “NALPAC” A NON-COMPARATIVE RANDOMIZED PHASE 2 STUDY, EVALUATING THE EFFICACY OF 5-FU + NALIRI AND 5-FU + NALIRINOX FOR METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), PROGRESSIVE AFTER GEMCITABINE-ABRAXANE OR GEMCITABINE MONOTHERAPY.

  NCT05472259· Groupe Belge D'Oncologie Digestive· Forrás

• APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

  NCT04858334· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 50
• Organoids 47
• Mendelian Randomization Analysis 29
• CRISPR-Cas Systems 16
• Gene Expression Profiling 123
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 3
• Exome Sequencing 10
• Proteomics 55
• Metabolomics 34
• Mass Spectrometry 10
• Flow Cytometry 32
• Immunohistochemistry 70
• Liquid Biopsy 30
• Circulating Tumor DNA 29
• Xenograft Model Antitumor Assays 302
• Positron-Emission Tomography 30
• Magnetic Resonance Imaging 117
• Machine Learning 58
• Deep Learning 55
• Cohort Studies 108
• Genome-Wide Association Study 24

• Microencapsulated tumor organoids maintain drug sensitivity stratification.

  Lab Chip, 2026. okt.

• CLDN18.2 targeting enhances chemotherapy sensitivity in pancreatic cancer cells and lung cancer organoids.

  Biochem Biophys Res Commun, 2026. szept.

• Multicellular rosette formation guides epithelial tissue assembly in pancreatic ductal adenocarcinoma cell organoids.

  Proc Natl Acad Sci U S A, 2026. szept.

• Real-time monitoring of CAR T cell dynamics in tumor patient-derived organoids using the OrganoIDNet algorithm.

  J Transl Med, 2026. szept.

• Multi-stromal organoid co-culture modelling reveals epithelial-fibroblast heterogeneity in pancreatic cancer and pancreatitis.

  Nat Cell Biol, 2026. szept.

• Chemotherapy-induced CAF-associated stromal remodeling in a humanized stroma pancreatic ductal adenocarcinoma organoid xenograft model: a comparison between GP and GS.

  Hum Cell, 2026. aug.

• Dual-oxygen pancreatic cancer organoids recapitulate basal-classical heterogeneity validated by spatial transcriptomics.

  Br J Cancer, 2026. aug.

• Expanded GEP-NET organoid culture for personalized therapy evaluation.

  Sci Adv, 2026. júl.

• Comparative evaluation of chemotherapy and CAR-T cell therapy in genetically engineered self-sustaining primary pancreatic cancer organoids.

  Pancreatology, 2026. júl.

• Pancreatic organoids and organoid-on-a-chip platforms: from disease modeling to precision therapy.

  J Transl Med, 2026. jún.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.